Search
Lilly and Camurus Forge Partnership to Jointly Develop Treatments for Obesity and Diabetes
2 week ago /
Read about 0 minute
Author：小编
Lilly and Camurus have inked a partnership agreement to collaboratively develop long-acting insulinotropic medications leveraging Camurus' FluidCrystal technology, aimed at treating metabolic disorders like obesity and diabetes. The agreement encompasses various drug compounds, notably GIP/GLP-1 receptor agonists. Pursuant to this agreement, Camurus stands to receive up to $870 million in potential milestone payments tied to development and sales achievements, along with royalties.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
